Ascendis Pharma A/S (ASND)
|Net Income (ttm)||-545.09M|
|Day's Range||156.98 - 169.84|
|52-Week Range||109.36 - 183.98|
|Price Target||195.76 (+16.3%)|
|Est. Earnings Date||Nov 10, 2021|
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorpo... [Read more...]
In 2020, ASND's revenue was 6.95 million, a decrease of -48.01% compared to the previous year's 13.38 million. Losses were -418.96 million, 92.2% more than in 2019.Financial numbers in millions EURFinancial Statements
According to 11 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price forecast is 195.76, which is an increase of 16.32% from the latest price.
Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Cont...
– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported –
Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.
COPENHAGEN, Denmark, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new trea...
Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 β/γ Clinical Program
– TransCon IL-2 β/γ is an investigational long-acting prodrug designed to improve cancer immunotherapy through the sustained systemic release of an IL-2 variant with potential for prolonged activation ...
COPENHAGEN, Denmark, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new trea...
COPENHAGEN, Denmark, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treat...
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – ...
Ascendis' (ASND) Skytrofa gets FDA approval for treating growth failure in pediatric patients. The drug is also the first FDA-approved product in the company's portfolio.
The pharmaceutical company saw its shares jump more than $26.
Approval of the company's weekly growth hormone is making investors smile today.
The FDA on Wednesday gave a thumbs-up to Ascendis Pharma A/S's (NASDAQ: ASND) long-acting growth hormone lonapegsomatropin-tcgd. Marketed as Skytrofa, the somatropin prodrug has been approved in kids ag...
– Announced U.S. Food and Drug Administration Approval of SKYTROFA ® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency –
Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the F...
- SKYTROFA, the first FDA approved treatment utilizing TransCon™ technology, is a long-acting prodrug of somatropin that releases the same somatropin used in daily therapies –
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
All it will take is an FDA approval and a partial repeat of history.
Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25
COPENHAGEN, Denmark, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates th...
COPENHAGEN, Denmark, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create new product candidate...
Ascendis (ASND) is seeking approval for lonapegsomatropin as a potential treatment of pediatric growth hormone deficiency.
The FDA has extended the ongoing review of the marketing application of Ascendis Pharma A/S's (NASDAQ: ASND) TransCon hGH (lonapegsomatropin) for the treatment of pediatric growth hormone deficiency. Ci...
Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapeg...
Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to September 25, 2021 Prescription Drug User Fee Act (PDUFA) goal date extended by three months...
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China...
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1 Somewhat Bullish 0 2 0 1 Indifferent ...
Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of W...
Online event to include a live reading by Children's Author, Ariana Feiner, whose short film documentary, A Story of Courage, has won 24 international awards Online event to include a live reading by Ch...
– Pre-launch activities continue in preparation for a potential FDA approval of TransCon™ hGH (lonapegsomatropin) for pediatric growth hormone deficiency; PDUFA date of June 25, 2021 –